Проблемы долгосрочной терапии деменции
Аннотация
В работе обсуждаются проблемы долгосрочной терапии деменции, приводятся сведения о факторах, играющих роль в формировании приверженности терапии больных, страдающих болезнью Альцгеймера, рассматриваются факторы, оказывающие влияние на организацию помощи дементным больным. Приводятся сведения о клинической и экономической эффективности применения акати-нола мемантина и возможности улучшения приверженности лечению при применении его однократной суточной дозы.
Об авторе
Наталья Михайловна Залуцкая
Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева
Россия
Россия
Список литературы
1. Белоусов Ю.Б. Зырянов С.К., Белоусов Д.Ю., Бекетов А.С. Клинико-экономические аспекты терапии болезни Альцгеймера в России. Качественная клиническая практика. - 2009. - № 1. - С. 3-28.
2. Белоусов Ю.Б., Чикина Е.С., Медников О.И. Фармакоэкономические аспекты лечения де-менции в РФ. - «РМЖ». - 2005. - № 20. - Т. 18. - С. 96-102.
3. Гаврилова С.И. Психические расстройства при первичных дегенеративных (атрофических) процессах головного мозга // Руководство по психиатрии. Под ред. А.С.Тиганова. - М.: Медицина. - 1999. - С. 57-117.
4. Любов Е. Б. Мемантин при болезни Альцгеймера: клиническая и экономическая позиции. Социальная и клиническая психиатрия. - 2008.
5. Министерство здравоохранения и социального развития РФ, Федеральное государственное бюджетное учреждение «Научный центр психического здоровья». Федеральные клинические рекомендации по диагностике и лечению болезни Альцгеймера. - Москва. - 2013. - 28 с.
6. Случевская С.Ф. Клинико-эпидемиологическая характеристика и организация медикосоциальной помощи психически больным пожилого возраста в Санкт-Петербурге: автореферат дис.. кандидата медицинских наук. - Санкт-Петербург. - 2008. - 28 с.
7. Agnew S.K., Morris R.G.: The heterogeneity of anosognosia for memory impairment in Alzheimer’s disease: a review of the literature and a proposed model. - Aging Ment Health.- 1998. - Vol. 2. - P. 7-19.
8. Alzheimer’s Association and National Alliance for Caregiving. - National Survey. - 2004.
9. Alzheimer’s Association. Alzheimer’s Disease Facts and Figures, Alzheimer’s Association, Alzheimer’s & Dementia. - 2014. - Vol. 10, Issue 2.
10. Alzheimer’s Association. Alzheimer’s Disease Facts and Figures. - 2011. - www.alz.org
11. Alzheimer’s Society. Dementia UK: Update, Second Edition. - 2014. - 114 р.
12. Antoine C., Antoine P., Guermonprez P., Frigard B.: Awareness of deficits and anosognosia in Alzheimer’s disease (in French). - Encephale. - 2004. - Vol. 30. - P. 570-577.
13. Banning M: Older people and adherence with medication: a review of the literature. Int J Nurs Stud. - 2008. - Vol. 45. - P. 1550-1561.
14. Barat I., Andreasen F., Damsgaard E.M. Drug therapy in the elderly: what doctors believe and patients actually do. Br J Clin Pharmacol. - 2001. - Vol. 51. - P. 615-622.
15. Bassil N., Grossberg G.T.: Novel regimens and delivery systems in the pharmacological treatment of Alzheimer’s disease. CNS Drugs. - 2009. - Vol. 23. - P. 293-307.
16. Beckman A.G., Parker M.G., Thorslund M.: Can elderly people take their medicine? Patient Educ Couns. - 2005. - Vol. 59. - P. 186-191.
17. Bickel H.: Epidemiologie dementieller Erkrankungen und ihre Auswirkungen auf das Sozial- und Gesundheitswesen. In: Psychogeriatrie in Europa - Modelle für Deutschland. Rottenburg-Stuttgart: Akademie der Diцzese. - 1995. - P. 7-16.
18. Birks J., Harvey R.J.: Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. - 2006. - CD001190.
19. Borah B., Sacco P., Zarotsky V.: Predictors of adherence among Alzheimer’s disease patients receiving orBlais L., Kettani F.Z., Perreault S., Leroux J.C., Forget A., Kergoat M.J.: Adherence to cholinesterase inhibitors in patients with Alzheimer’s disease. J Am Geriatr Soc. - 2009. - Vol. 57. - P. 366-368.
20. Clare L., Goater T., Woods B. Illness representations in early-stage dementia: a preliminary investigation. - Int J Geriatr Psychiatry. - 2006. - Vol. 21. - P. 761-767.
21. Corsonello A., Pedone C., Lattanzio F., Lucchetti M., Garasto S., Carbone C., Greco C., Fabbietti P., Incalzi RA: Regimen complexity and medication nonadherence in elderly patients. - Ther Clin Risk Manag. - 2009. - Vol.5. - P.209-216.
22. Cotrell V., Wild K., Bader T.: Medication management and adherence among cognitively impaired older adults. - J Gerontol Soc Work. - 2006.-Vol. 47. - P. 31-46.
23. Dementia: An Austrian Cohort Study. Alzheimer Dis Assoc Disord. 2013. - Oct 9.
24. Gadzhanova S., Roughead L., Mackson J.: Anticholinesterase duration in the Australian veteran population. Aust NZ J Psychiatry. - 2010. - Vol. 44. - P. 469-474.
25. Haider B., Schmidt R., Schweiger C., et al. Medication Adherence in Patients With
26. Hallauer J. Wirklichkeit der Pharmakotherapie bei Heimbewohnern mit Demenz - Ergebnisse einer neuen Felduntersuchung in 23 Pflegeheimen, Krankenpflege Journal. - 2005. - Vol. 43. - P. 206.
27. Hansen R.A., Gartlehner G., Webb A.P., et al. Efficacy and safety of donepezil, galantamine and rivastigmine for the treatment of Alzheimer’s disease: a systemic review and meta- analysis. - Clin Intervent Aging.- 2008. - Vol. 3. - P. 211-225.
28. Hanyu H., Sakurai H., Hirao K., Shimizu S., Iwamoto T.: Unawareness of memory deficits depending on cerebral perfusion pattern in mild cognitive impairment. - J Am Geriatr Soc. - 2007. - Vol. 55. - P. 470-471.
29. Herrmann N., Binder C., Dalziel W., Smyth S., Camacho F.: Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study. - Drugs Aging. - 2009. - Vol. 26. - P. 403-407.
30. Hill J., Fillit H., Thomas S.K., Chang S.: Functional impairment, healthcare costs and the prevalence of institutionalisation in patients with Alzheimer’s disease and other dementias. - Pharmacoeconom-ics. - 2006. - Vol. 24. - P. 265-280.
31. Howe E.: Improving the quality of life in patients with Alzheimer’s disease. - Psychiatry (Edgmont). - 2008. - Vol. 5. - P. 51-56.
32. IMS HEALTH, Institut fuer medizinische Statistik, Patientendatenbank Disease Analyzer, 2006 Cit. nach Jagsch Ch. Wo stehen wir in der Behandlung mit Antidementiva? Antidementive Therapie bei kognitiven Symptomen und Verhaltensstцrungen bei Demenz. LSF Graz. Gerontopsychiatrischer Samstag. - 2010.
33. Jones R.W., Bayer A., Inglis F., Barker A., Ravinder Ph. Safety and tolerability of once-daily versus twicedaily memantine: a randomised, double-blind study in moderate to severe Alzheimer’s disease Int. J. Geriatr. - Psychiatry. - 2007. - Vol. 22. - P. 258262.
34. Kairuz T., Bye L., Birdsall R., Deng T., Man L., Ross A., Samarasinha I., Tautolo E.: Identifying compliance issues with prescription medicines among older people: a pilot study. - Drugs Aging. - 2008. - Vol. 25. - P. 153-162.
35. Kashiwa Y., Kitabayashi Y., Narumoto J., Nakamura K., Ueda H., Fukui K.: Anosognosia in Alzheimer’s disease: association with patient characteristics, psychiatric symptoms and cognitive deficits. - Psychiatry Clin Neurosci. - 2005. - Vol. 59. - P. 697-704.
36. Kraft E., Marti M., Werner S., Sommer H. Cost of dementia in Switzerland. Swiss Med Wkly - 2010. -140: w13093 (Update: 2011).
37. Kroger E., van Marum R., Souverein P., Egberts T.: Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Neth erlands: a retrospective cohort study. - Drugs Aging. - 2010. - Vol. 27. - P. 663-675.
38. Massoud F., Belleville S., Bergman H., Kirk J., Chertkow H., Nasreddine Z., Joanette Y., Freedman M.: Mild cognitive impairment and cognitive impairment, no dementia: part B, therapy. Alzheimers Dement. - 2007. - Vol. 3. - P. 283-291.
39. Massoud F., Dorais M., Charbonneau C., Lescrau-waet B., Boucher J.M., LeLorier J.: Drug utilization review of cholinesterase inhibitors in Quebec. - Can J Neurol Sci. - 2008. - Vol. 35. - P. 508-509.
40. Massoud F., Gauthier S.: Update on the pharmacological treatment of Alzheimer’s disease. - Curr Neuropharmacol. - 2010. - Vol. 8. - P. 69-80.
41. McShane R., Areosa S.A., Minakaran N. Me-mantine for dementia. Cochrane Database Syst Rev. - 2006. - Vol. 16: CD003154.
42. Michon A., Deweer B., Pillon B., Agid Y., Dubois B.: Relation of anosognosia to frontal lobe dysfunction in Alzheimer’s disease. - J Neurol Neurosurg Psychiatry. - 1994. - Vol. 57. - P. 805-809.
43. Molinuevo J.L., Hernandez B.: Assessment of the information provided by the medical specialist on Alzheimer’s disease and that retained by the patient caregivers. - Neurologia. - 2012. - Vol. 27. - P. 453-471.
44. Molinuevo J.L., Hernandez B.: Profile of the informal carer associated with the clinical management of the Alzheimer’s disease patient refractory to symptomatic treatment of the disease. - Neurologia. - 2011. - Vol. 26. - P. 518-527.
45. Monsch A.U., Buela C., Hermelink M., Kressig R.W., Martensson B., Mosimann U., Muri R., Vogeli S., von Gunten A., Schweizer Expertengruppe Konsensus 2012 zur Diagnostik und Therapie von Demenzkranken in der Schweiz. - 2012.
46. National Clinical Practice Guideline Number 42 National Collaborating Centre for Mental Health. A NICE-SCIE Guideline on supporting people with dementia and their carers in health and social care. - The British Psychological Society and Gaskell. - 2007.
47. Osterberg L., Blaschke T., Adherence to medication. - N Engl J Med. - 2005. - Vol. 353. - P 487-497.
48. Peskind E.R., Potkin S.G., Pomara N., Ott B.R., Graham S.M., Olin J.T., McDonald S. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. - Am J Geri-atr Psychiatry. - 2006. - Vol. 14. - P. 704-715.
49. Reed B.R., Jagust W.J., Coulter L.: Anosognosia in Alzheimer’s disease: relationships to depression, cognitive function, and cerebral perfusion. - J Clin Exp Neuropsychol. - 1993. - Vol. 15. - P. 231-244.
50. Riepe M.W., Ibach B.: Neurological and psychiatric practitioners’ views on Alzheimer’s disease and treatment thereof. Dement Geriatr Cogn Disord. - 2008. - Vol. 26. - P. 541-546.
51. Roberts J.S., Connell C.M.: Illness representations among first-degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord. - 2000. - Vol. 4. - P. 129-136; discussion 127-128.
52. Rountree S.D., Chan W., Pavlik V.N., Darby E.J., Siddiqui S. Doody R.S. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease Alzheimers Res Ther. - 2009. - Vol. 1. - P. 7.
53. Ruof J. et al. Diffusion of innovations: treatment of Alzheimer/s disease in Germany. - Health Policy. - 2002. - Vol. 60. - P. 59-66.
54. Rychlik R. Gutachten ueber die Unterversorgung mit Arzneimitteln in Deutschland Addendum Institut fuer Empirische Gesundheitsцkonomie. - 2007. - 79 pp.
55. Schwalbe O., Scheerans C., Freiberg I., Schmidt-Pokrzywniak A., Stang A., Kloft C.: Compliance assessment of ambulatory Alzheimer patients to aid therapeutic decisions by healthcare professionals. BMC Health Serv Res. - 2010. - Vol. 10. - P. 232.
56. Schweizerische Alzheimervereinigung/gfs.bern. Leben mit Demenz in der Schweiz - Eckdaten 2 - Aktuelle Versorgung. Studie im Auftrag der Schweizerischen Alzheimervereinigung. - Bern. - 2004.
57. Sedaghat F., Dedousi E., Baloyannis I., Tegos T., Costa V., Dimitriadis A.S., Baloyannis S.J.: Brain SPECT findings of anosognosia in Alzheimer’s disease. - J Alzheimers Dis. - 2010. - Vol. 21. - P. 641-647.
58. Shibata K., Narumoto J., Kitabayashi Y., Ushijima Y., Fukui K.: Correlation between anosognosia and regional cerebral blood flow in Alzheimer’s disease. Neurosci Lett. - 2008. - Vol. 435. - P. 7-10.
59. Small G., Dubois B.: A review of compliance to treatment in Alzheimer’s disease: potential benefits of a transdermal patch. Curr Med Res Opin. - 2007. - Vol. 23. - P. 2705-2713.
60. Starkstein S.E., Jorge R., Mizrahi R., Robinson R.G.: A diagnostic formulation for anosognosia in Alzheimer’s disease. - J Neurol Neurosurg Psychiatry. - 2006. - Vol. 77. - P. 719-725.
61. Tordoff J.M., Bagge M.L., Gray A.R., Campbell A.J., Norris P.T.: Medicine-taking practices in community-dwelling people aged > or =75 years in New Zealand. Age Ageing. - 2010. - Vol. 39. - P. 574-580.
62. Tremont G., Alosco M.L.: Relationship between cognition and awareness of deficit in mild cognitive impairment. - Int J Geriatr Psychiatry. - 2011. - Vol. 26. - P. 299-306.
63. Tseng Ch., Yang Y.-H., Chen Ch.-H. Clinical adherence of taking memantine in moderate-to-severe alzheimers disease in Taiwan. Alzheimer’s and Dementia. j. of the Alzheimer’s Ass. - 2013. - Vol. 9, Issue 4, Supplement. - P. 881.
64. van der Steen JT. Dying with dementia: what we know after more than a decade of research. - J Alzheimers Dis. - 2010. - Vol. 22. - P. 37-55.
65. Vogel A., Hasselbalch S.G., Gade A., Ziebell M., Waldemar G.: Cognitive and functional neuroimaging correlate for anosognosia in mild cognitive impairment and Alzheimer’s disease. - Int J Geriatr Psychiatry. - 2005. - Vol. 20. - P. 238-246.
66. Wilcock et al. Memantine for agitation/aggression and psychosis in moderately servere to servere Alzheimer’s disease:a pooled analysis of 3 studies. Journal of Clinical Psychiatry. - 2008. - Vol. 69. - P. 341-348.
67. Wilkinson et al. Analysis of the Effect of Memantine in Reducing the Worsening of Clinical Symptoms in Patients with Moderate to Severe Alzheimer’s Disease. - Dementia and Geriatric Cognitive Disorders. - 2007. - Vol. 24. - P. 138-145.
68. Wimo A., Winblad B., Stoeffler A., et al. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer’s disease. - Pharmacoeconomics. - 2003. - Vol. 21. - P. 327-340.
69. Winblad B., Jones R.W., Wirth Y., et al.: Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials. - Dement Geriatr Cogn Disord. - 2007. - Vol. 24. - P. 20-27.
70. Wolf-Klein G., Pekmezaris R., Chin L. and Weiner J. Conceptualizing Alzheimer’s disease as a terminal medical illness. Am J Hosp Palliat Care. - 2007. - Vol. 24. - P. 77-82.
71. Wolstenholme J., Fenn P., Gray A., Keene J., Jacoby R., Hope T.: Estimating the relationship between disease progression and cost of care in dementia. Br J Psychiatry. - 2002. - Vol. 181. - P.36-42.
72. World Health Organization. Dementia: a public health priority. - WHO. - 2012. (www.who.int/mental_health/neurology/dementia/en/).6]
73. Zanetti O., Solerte S.B. and Cantoni F. Life expectancy in Alzheimer’s disease (AD). - Arch Gerontol Geriatr. - 2009. - Vol.49. - P.237-243.
74. http://www.alz.org/facts/.
75. http://www.rxlist.com/namenda-drug/clinicalpharmacology.htm
Рецензия
Для цитирования:
Залуцкая Н.М. Проблемы долгосрочной терапии деменции. Обозрение психиатрии и медицинской психологии имени В.М.Бехтерева. 2016;(2):78-85.
For citation:
Zalutskaya N.M. Problems of long-term therapy of dementia. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2016;(2):78-85. (In Russ.)
Просмотров: 347
Послать статью по эл. почте 